While there is skepticism about the US Food and Drug Administration’s ability to meet fast-approaching deadlines under the Modernization of Cosmetic Regulations Act of 2022, attorneys agree that companies need to be preparing in earnest.
“Based on my long experience in this industry and having had the exposure to the lobbyists who are the NGOs and [to] Congress, I would expect FDA is going to be pressured to bring enforcement actions,” said Sharon Blinkoff, senior counsel at the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?